A major clinical trial found that one in five people with chronic hepatitis B could control the virus without further ...

A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s called a “functional cure,” researchers reported Thursday.

Drug candidate bepirovirsen delivered a functional cure rate for 19% of patients in what the company sees as a breakthrough ...

Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these ...

The sneaky virus poses serious health threats if it goes on to become a chronic disease. Clinical trial results suggest a new drug may cure 1 in 5 of those cases.

A single hepatitis B injection set off a lasting immune response, and two patients reached a functional cure that held for ...

Across two large trials, roughly 20% of people treated with bepirovirsen had undetectable levels of the virus after stopping ...

The antisense oligonucleotide was even more effective in patients with relatively low viral activity. More than one-quarter of these individuals had undetectable levels of the virus in the blood for ...

The recent publication of a research paper on a drug trial has given hope to millions of patients with chronic hepatitis B ...

New research implies that a first-of-its-kind drug for hepatitis B could allow some patients to stop treatment without ...